SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial (LIFETIME) – rationale, methodology and design
View ORCID ProfileReiner Jumpertz von Schwartzenberg, View ORCID ProfileNorbert Stefan, View ORCID ProfileRobert Wagner, Martina Guthoff, View ORCID ProfileArvid Sandforth, View ORCID ProfileAndrea Icks, Matthias Blüher, Jochen Seissler, Julia Szendrödi, Michael Roden, View ORCID ProfileChristoph Wanner, View ORCID ProfileHiddo J. L. Heerspink, View ORCID ProfileHubert Preissl, View ORCID ProfileAndreas Fritsche, View ORCID ProfileAndreas L. Birkenfeld
doi: https://doi.org/10.1101/2023.11.18.23298622
Reiner Jumpertz von Schwartzenberg
1Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
2German Center for Diabetes Research (DZD), Neuherberg, Germany
3Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, University Clinic Tübingen, Tübingen, Germany
Norbert Stefan
1Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
2German Center for Diabetes Research (DZD), Neuherberg, Germany
3Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, University Clinic Tübingen, Tübingen, Germany
Robert Wagner
2German Center for Diabetes Research (DZD), Neuherberg, Germany
4Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
5Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine University, Düsseldorf, Germany
Martina Guthoff
1Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
2German Center for Diabetes Research (DZD), Neuherberg, Germany
3Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, University Clinic Tübingen, Tübingen, Germany
Arvid Sandforth
1Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
2German Center for Diabetes Research (DZD), Neuherberg, Germany
3Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, University Clinic Tübingen, Tübingen, Germany
Andrea Icks
2German Center for Diabetes Research (DZD), Neuherberg, Germany
6Institute for Health Services Research and Health Economics, Centre for Health and Society, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
7Institute for Health Services Research and Health Economics, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
Matthias Blüher
2German Center for Diabetes Research (DZD), Neuherberg, Germany
8Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig, Leipzig, Germany
Jochen Seissler
2German Center for Diabetes Research (DZD), Neuherberg, Germany
9Diabetes Research Group, Medical Department 4, Ludwig-Maximilians University Munich, Munich, Germany
Julia Szendrödi
2German Center for Diabetes Research (DZD), Neuherberg, Germany
10Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Germany
Michael Roden
2German Center for Diabetes Research (DZD), Neuherberg, Germany
4Division of Endocrinology and Diabetology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany
5Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich-Heine University, Düsseldorf, Germany
Christoph Wanner
11Division of Nephrology, University Hospital of Würzburg, Würzburg, Germany
Hiddo J. L. Heerspink
12The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
13Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center, Groningen, Netherlands
Hubert Preissl
1Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
2German Center for Diabetes Research (DZD), Neuherberg, Germany
Andreas Fritsche
1Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
2German Center for Diabetes Research (DZD), Neuherberg, Germany
3Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, University Clinic Tübingen, Tübingen, Germany
Andreas L. Birkenfeld
1Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen, Tübingen, Germany
2German Center for Diabetes Research (DZD), Neuherberg, Germany
3Department of Internal Medicine, Division of Endocrinology, Diabetology and Nephrology, University Clinic Tübingen, Tübingen, Germany
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability Statement
The datasets generated during the study are not available publicly because they are subject to national data protection laws and restrictions imposed by the ethics committee to ensure privacy of study participants. However, they can be requested after the primary publication through an individual project agreement with the corresponding author. The request will be reviewed by the data steering committee. A data access agreement will have to be reached after request approval.
Posted November 18, 2023.
SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial (LIFETIME) – rationale, methodology and design
Reiner Jumpertz von Schwartzenberg, Norbert Stefan, Robert Wagner, Martina Guthoff, Arvid Sandforth, Andrea Icks, Matthias Blüher, Jochen Seissler, Julia Szendrödi, Michael Roden, Christoph Wanner, Hiddo J. L. Heerspink, Hubert Preissl, Andreas Fritsche, Andreas L. Birkenfeld
medRxiv 2023.11.18.23298622; doi: https://doi.org/10.1101/2023.11.18.23298622
SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial (LIFETIME) – rationale, methodology and design
Reiner Jumpertz von Schwartzenberg, Norbert Stefan, Robert Wagner, Martina Guthoff, Arvid Sandforth, Andrea Icks, Matthias Blüher, Jochen Seissler, Julia Szendrödi, Michael Roden, Christoph Wanner, Hiddo J. L. Heerspink, Hubert Preissl, Andreas Fritsche, Andreas L. Birkenfeld
medRxiv 2023.11.18.23298622; doi: https://doi.org/10.1101/2023.11.18.23298622
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (671)
- Anesthesia (181)
- Cardiovascular Medicine (2657)
- Dermatology (224)
- Emergency Medicine (401)
- Epidemiology (12255)
- Forensic Medicine (10)
- Gastroenterology (765)
- Genetic and Genomic Medicine (4117)
- Geriatric Medicine (387)
- Health Economics (681)
- Health Informatics (2667)
- Health Policy (1007)
- Hematology (364)
- HIV/AIDS (854)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (440)
- Neurology (3900)
- Nursing (210)
- Nutrition (579)
- Oncology (2041)
- Ophthalmology (586)
- Orthopedics (242)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (452)
- Public and Global Health (6542)
- Radiology and Imaging (1407)
- Respiratory Medicine (871)
- Rheumatology (411)
- Sports Medicine (343)
- Surgery (452)
- Toxicology (54)
- Transplantation (185)
- Urology (167)